Lot-document scope confirmed before quotation · Research use only
  • Specification Review
  • Lot Documents on Request
  • Business Support · Xi’an
  • Destination Eligibility Confirmed
西安诺和达生物科技有限公司

Research & insights

hCG Evidence Guide: Official Label, Trials and Claim Boundaries

By NHD Technical TeamPublished Updated Sep 8, 2026

Human chorionic gonadotropin has established reproductive biology and regulated finished-drug uses. Those facts do not make every hCG source, glycoform or catalog material interchangeable.

Evidence at a glance

  • DailyMed describes Pregnyl as a urine-derived preparation standardized by biological assay and supplied as 10,000 USP units per vial.
  • The 2018 PubMed abstract reports 282 randomized men and shows arm counts that are internally inconsistent with that total; the total and arm denominators should be verified from the full paper before reuse.
  • A 2026 open-label randomized study of 45 men with congenital hypogonadotropic hypogonadism found no significant between-group difference in spermatogenesis rates.
Documentary reproductive-endocrinology evidence review
AI-generated editorial illustration illustrating the research workflow. It is not a study figure, patient image, product photograph, assay result or catalog lot.

Study record

The Pregnyl label identifies a highly purified urine-derived polypeptide hormone and specifies biological activity in USP units. It also defines indications, contraindications and monitoring; these finished-product facts cannot be copied to an unspecified research material.

2018 trialPubMed abstract reports 282 total; verify displayed arm counts in the full paper
TestosteroneMean rose from 2.31 ± 0.66 to 5.17 ± 1.77 nmol/L; no significant between-group difference
2026 trial45 adult men; three gonadotropin strategies
Spermatogenesis84.6%, 69.2% and 75.0%; p=0.648
Finished-drug boundaryLabel applies to Pregnyl formulation, potency and supervised indications

Results in context

In the 2018 trial, mean testosterone rose from 2.31 ± 0.66 nmol/L at baseline to a final mean of 5.17 ± 1.77 nmol/L across groups, with no significant between-group difference. The PubMed abstract reports 282 randomized participants but displays arm counts that do not reconcile with that total, so arm-level denominators require full-text verification.

The 2026 trial compared three supervised fertility-induction strategies. The small sample and nonsignificant between-group differences support cautious interpretation rather than a hierarchy of efficacy.

What the evidence cannot establish

Trials address selected diagnosed populations under medical supervision.

USP units are biological-activity units, not milligrams.

Labeling for a named regulated drug does not validate a catalog lot or another source.

Sources & editorial method

This article discusses the source records listed below, with the study models and limitations stated alongside the findings. AI-assisted drafting and image generation were used. The reference list identifies the records behind this article; it is not an independent peer review or verification of a supplied catalog lot.

4 linked records are listed in the references below. Read the editorial and AI-assistance policy.

How to interpret this article

Source-checked on 2026-09-02. Null results, sample size, model/population limits, finished-drug scope, regulatory status and product-evidence boundaries are retained. This is not medical advice, a customer case or validation of a catalog lot.

Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.

Primary records and authoritative sources

  1. DailyMed Pregnyl labelOfficial U.S. prescription labeling and product description.
  2. Randomized comparison of clomiphene, hCG and combination therapyPubMed abstract reports 282 randomized participants; displayed arm counts require full-text verification. PMID 29772111.
  3. Gonadotropin strategies in congenital hypogonadotropic hypogonadism2026 open-label randomized study of 45 men; PMID 41993983.
  4. The biology of human chorionic gonadotropinReview. 2018. PMID 29772831.
Research pathways

Continue with structured records

Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.

Editorial source check: Site evidence editorial team · 2026-09-02